



Update 2_0_296

Clinical Reminders

VA-COVID-19 TEMPLATE UPDATES Install Guide

July 2022

Product Development
Office of Information Technology
Department of Veterans Affairs

Table of Contents

INTRODUCTION	1
INSTALL DETAILS	4
INSTALL EXAMPLE	5
POST INSTALLATION	7

Introduction

Description:

COVID-19 Telephone Follow Up note:

- Updates to display the symptom onset date and/or exposure date from screening template (last two weeks) This will assist the user completing the template when reviewing isolation criteria.
- Update to change Infection Control discussion from referral to review.
- Update to vaccine guidance in plan
- New option for offering treatment in plan (local section)
- Updates to more clearly reflect guidance for isolation

COVID-19 Discharge template (also embedded in COVID-19 provider screen note)

- Updates to more clearly reflect guidance for isolation

COVID-19 Immunization reminder and template

- Added links for Novavax EAU fact sheets for providers and patients.

1. Update to telephone note – symptom onset and exposure date entered on covid screen template now display above the care disposition section, isolation information updated to include mask wearing and separate symptomatic into mild and moderate:

07/13/2022 COVID-19 Symptom Onset Date
07/10/2022 COVID-19 Exposure Date

Care Disposition*

Positive COVID-19 must ISOLATE

- Regardless of vaccination status
- Day 0 is the first day of symptoms or a positive viral test. The count of days starts the next full day.
- Asymptomatic patients may end isolation after 5 full days.
Wear a mask through day 10.
- Symptomatic patients (mild illness) may end isolation after 5 full days if fever-free (without fever-reducing medication use) and symptoms have improved.
Wear a mask through day 10.
- Symptomatic patient (Moderate illness, symptoms that affect the lungs) should isolate for 10 days.

[COVID-19 Quarantine and Isolation | CDC](#)

++ For severely ill or immunocompromised patients, care team to review case with provider before ending isolation, after at least 10 days ++

Indicate patient condition*

- Meets CDC guidelines to end isolation.
- Does not meet CDC guidelines to end isolation.
- Provider reviewed and meets CDC guidelines to end isolation (i.e., severe illness, improving, 10 days have passed, no concerns to maintain isolation).
- Provider reviewed and DOES NOT meet CDC guidelines to end isolation (i.e., severe illness, improving, 10 days have passed, no concerns to maintain isolation).

2. Telephone Note – Plan section – Immunocompromised condition and Vaccine Guidance section updated

Plan and Patient Education

- Continue telephone contact follow up
- Use ANNIE app for follow-up
- Instruct Veteran to secure message Primary Care Provider/team
- Contact the VA Nurse Advice Line by calling your main VA medical center and selecting the option to speak to a nurse for new or worsening symptoms. Call 911 if immediate medical attention is needed for shortness of breath or other symptoms and notify 911 personnel of home monitoring for possible COVID-19.
- Provide information on preventing the spread of COVID-19
- Follow up with Primary Care Provider/team.
- Patient has severe immunocompromised condition. Patient may benefit from Infection Control team review. Will notify Primary Care Provider/team.
- Vaccine guidance
 - Patient has not received COVID-19 vaccination.
 - Advised to get vaccinated after completion of isolation/quarantine.
 - Given information on receiving vaccine through VA or local clinics.
 - Had complications and will speak with Primary Care Provider regarding when to receive vaccine.
 - Patient has started vaccination. Due to receive next dose on .

3. Telephone Note - New group available for sites to include/add to the plan section if they would like to. All the specific treatment options install disabled and you can choose which options to enable based on what treatment options are available for your patients, this dialog group is also locally editable, you can add additional elements that represent other treatment options if needed:

- Discussed treatment options available
 - Nirmatrelvir/Ritonavir (Paxlovid) - 5 day oral course (boosted protease inhibitor, contraindicated with salmeterol or rivaroxaban; [Management of Drug Interactions With Nirmatrelvir/Ritonavir \(Paxlovid\)](#))
 - NURSES: Provider notified of patient's interest in treatment.

Comment:
 - PROVIDERS: Patient/surrogate gave oral informed consent to the treatment plan.
 - PROVIDERS: Patient/surrogate did not consent to the treatment plan.
 - Bebtelovimab - single dose IV (monoclonal antibody)
 - NURSES: Provider notified of patient's interest in treatment.
 - PROVIDERS: Patient/surrogate gave oral informed consent to the treatment plan.
 - PROVIDERS: Patient/surrogate did not consent to the treatment plan.
 - Molnupiravir - 5 day oral course (polymerase-active agent, contraindicated in pregnancy, requires contraception)
 - NURSES: Provider notified of patient's interest in treatment.
 - PROVIDERS: Patient/surrogate gave oral informed consent to the treatment plan.
 - PROVIDERS: Patient/surrogate did not consent to the treatment plan.

Reason patient declined and expected outcome:
 - Remdesivir - 3 daily IV infusions (polymerase inhibitor)
 - NURSES: Provider notified of patient's interest in treatment.
 - PROVIDERS: Patient/surrogate gave oral informed consent to the treatment plan.
 - PROVIDERS: Patient/surrogate did not consent to the treatment plan.

4. Discharge note – suspected and positive Isolation criteria updated to include mask wearing and separate symptomatic into mild and moderate, these items are also in the provider screen discharge instructions as well

Steps to prevent the spread of COVID-19

Positive COVID-19 must ISOLATE

- Regardless of vaccination status
- Day 0 is the first day of symptoms or a positive viral test. The count of days starts the next full day.
- Asymptomatic patients may end isolation after 5 full days. Wear a mask through day 10.
- Symptomatic patients (mild illness) may end isolation after 5 full days if fever-free (without fever-reducing medication use) and symptoms have improved. Wear a mask through day 10.
- Symptomatic patient (Moderate illness, symptoms that affect the lungs) should isolate for 10 days.

[COVID-19 Quarantine and Isolation | CDC](#)

++ For severely ill or immunocompromised patients review specific CDC guidance on ending isolation. ++

Indicate patient condition - for provider review

5. The hyperlink in the field HYPERLINK COVID-19 HOW TO PROTECT SELF was updated to the correct CDC page.
6. NOVAVAX information added to detailed information section in COVID-19 reminder dialog.

COVID-19 Vaccine Information Fact Sheets and EUA Fact Sheets

Moderna Fact Sheet for Providers	Moderna VIS for Recipients and Caregivers
Pfizer Fact Sheet for Providers	Pfizer VIS and EUA Fact Sheet for Recipients and Caregivers
Janssen EUA Fact Sheet for Providers	Janssen EUA Fact Sheet for Recipients and Caregivers
Novavax EUA Fact Sheet for Providers	Novavax EUA Fact Sheet for Recipients and Caregivers

UPDATE_2_0_296 contains 1 Reminder Exchange entry:
UPDATE_2_0_296 VA-COVID-19 TEMPLATE UPDATES

The exchange file contains the following components:
REMINDER GENERAL FINDINGS
VIEW PROGRESS NOTE TEXT

TIU TEMPLATE FIELD

HYPERLINK COVID-19 PREVENT SPREAD
HYPERLINK COVID-19 HOW TO PROTECT SELF
VA-CDC QUARANTINE ISOLATION
DATE
VA-COVID PAXLOVID LINK

HEALTH FACTORS

VA-REMINDER UPDATES [C]
VA-UPDATE_2_0_296
VA-COVID-19 [C]
VA-COVID-19 UNABLE TO CARE FOR SELF HOME
VA-COVID-19 CAN CARE FOR SELF AT HOME
VA-COVID-19 EXPOSURE DATE
VA-COVID-19 SYMPTOM ONSET DATE
VA-COVID-19 PLAN DISCUSS TREATMENT REMDESIVIR
VA-COVID-19 PLAN DISCUSS TREATMENT MOLNUPIRAVIR
VA-COVID-19 PLAN DISCUSS TREATMENT BEBTELOVIM
VA-COVID-19 PLAN DISCUSS TREATMENT PAXLOVID

REMINDER TERM

VA-REMINDER UPDATE_2_0_296

HEALTH SUMMARY TYPE

VA-COVID-19 EXPO SYMP DATE

HEALTH SUMMARY OBJECTS

VA-COVID-19 EXPOSURE SYMPTOM DATE (TIU)

TIU DOCUMENT DEFINITION

VA-COVID-19 EXPOSURE SYMPTOM DATE

REMINDER DIALOG

VA-GP COVID-19 UPDATE JUNE 2022

Install Details

Installation:

=====

This update can be loaded with users on the system. Installation will take less than 5 minutes.

This update is being distributed as a web host file. The address for the host file is:

https://REDACTED/UPDATE_2_0_296.PRD

The file will be installed using Reminder Exchange, programmer access is not required.

Install Example

To Load the Web Host File. Navigate to Reminder exchange in Vista

```
+      + Next Screen  - Prev Screen  ?? More Actions  >>>
CFE  Create Exchange File Entry      LHF  Load Host File
CHF  Create Host File                 LMM  Load MailMan Message
CMM  Create MailMan Message           LR   List Reminder Definitions
DFE  Delete Exchange File Entry       LWH  Load Web Host File
IFE  Install Exchange File Entry       RI   Reminder Definition Inquiry
IH   Installation History              RP   Repack
Select Action: Next Screen// lwh      Load Web Host File
Input the URL for the .prd file: https://[REDACTED]/UPDATE_2_0_296.PRD
```

At the **Select Action:** prompt, enter **LWH** for Load Web Host File

At the **Input the url for the .prd file:** prompt, type the following web address:
https://REDACTED/UPDATE_2_0_296.PRD

You should see a message at the top of your screen that the file loaded successfully

```
https://[REDACTED]/UPDATE_2_0_296.PRD successfully loaded.
```

Search and locate an entry titled **UPDATE_2_0_296 VA-COVID-19 TEMPLATE UPDATES** in reminder exchange.

```
+Item  Entry                                     Source  Date Packed
424    UPDATE_2_0_296 VA-COVID-19 TEMPLATE UPDATES
425    UPDATE_2_0_2_2 CAREGIVER ELIG
426    UPDATE_2_0_30 VA-IRAQ &
      AFGHAN POST-DEPLOY
427    UPDATE_2_0_31 VA-REACH
428    UPDATE_2_0_32 VA-MH
      CONTINGENCY MANAGEMENT
429    UPDATE_2_0_33 MISC UPDATE 4
430    UPDATE_2_0_33 MISC UPDATE 4
+      + Next Screen  - Prev Screen  ?? More Actions  >>>
CFE  Create Exchange File Entry      LHF  Load Host File
CHF  Create Host File                 LMM  Load MailMan Message
CMM  Create MailMan Message           LR   List Reminder Definitions
DFE  Delete Exchange File Entry       LWH  Load Web Host File
IFE  Install Exchange File Entry       RI   Reminder Definition Inquiry
IH   Installation History              RP   Repack
Select Action: Next Screen// IFE      Install Exchange File Entry
Enter a list or range of numbers (1-661): 424
```

At the **Select Action** prompt, enter **IFE** for Install Exchange File Entry

Enter the number that corresponds with your entry **UPDATE_2_0_296 VA-COVID-19 TEMPLATE UPDATES** (in this example it is entry 424 it will vary by site). The date of the exchange file should be 07/26/2022.

```

Component                                     Category  Exists
Source:
Date Packed:
Package Version: 2.0P71

Description:
The following Clinical Reminder items were selected for packing:
REMINDER DIALOG
  VA-GP COVID-19 UPDATE JUNE 2022

REMINDER TERM
  VA-REMINDER UPDATE_2_0_296

Keywords:

Components:

+ Enter ?? for more actions >>>
IA Install all Components          IS Install Selected Component
Select Action: Next Screen// IA

```

At the **Select Action** prompt, type **IA** for Install all Components and hit enter.
 Select Action: Next Screen// **IA Install all Components**
 You will see several prompts, for all new entries you will choose **I to Install**
*For components that already exists but the packed component is different, you will choose **O to Overwrite**.*

You will be prompted to install the reminder dialog component – You will choose to install all even though some components may have an X to indicate that they exist.

```

Packed reminder dialog: VA-GP COVID-19 UPDATE JUNE 2022 [NATIONAL DIALOG]

```

Item	Seq.	Dialog Findings	Type	Exists
1		VA-GP COVID-19 UPDATE JUNE 2022 Finding: *NONE*	group	
2	1	VAL-SARS-COV-2 VACCINE INFO TEXT EUA URLs Finding: *NONE*	element	X
3	2	VA-COVID-19 EDUCATION LINK SELF CARE Finding: *NONE*	element	X
4	5	VA-COVID-19 FOLLOW-UP CALL VERSION Finding: *NONE*	element	X
5	10	VA-GP COVID-19 FOLLOW-UP CARE DISPOSITION FU Finding: *NONE*	group	X
6	10.5	VAL-COVID-19 STOP HOME ISOLATION INFO FU	group	X

```

+ + Next Screen - Prev Screen ?? More Actions
DD Dialog Details      DT Dialog Text          IS Install Selected
DF Dialog Findings     DU Dialog Usage        QU Quit
DS Dialog Summary      IA Install All
Select Action: Next Screen// IA Install All

```

At the **Select Action** prompt, type **IA** to install the dialog – **VA-GP COVID-19 UPDATE JUNE 2022**

Select Action: Next Screen// **IA Install All**

Install reminder dialog and all components with no further changes: Y// **Yes**


```

Packed reminder dialog: VA-GP COVID-19 UPDATE JUNE 2022 [NATIONAL DIALOG]
VA-GP COVID-19 UPDATE JUNE 2022 (group) installed from exchange file.
Item  Seq. Dialog Findings                               Type  Exists
  1    VA-GP COVID-19 UPDATE JUNE 2022                   group  X
      Finding: *NONE*
  2    1 VAL-SARS-COV-2 VACCINE INFO TEXT EUA URLS       element X
      Finding: *NONE*
  3    2 VA-COVID-19 EDUCATION LINK SELF CARE            element X
      Finding: *NONE*
  4    5 VA-COVID-19 FOLLOW-UP CALL VERSION              element X
      Finding: *NONE*
  5    10 VA-GP COVID-19 FOLLOW-UP CARE DISPOSITION FU   group  X
      Finding: *NONE*
  6    10.5 VAL-COVID-19 STOP HOME ISOLATION INFO FU    group  X
+      + Next Screen  - Prev Screen  ?? More Actions
DD  Dialog Details      DT  Dialog Text      IS  Install Selected
DF  Dialog Findings    DU  Dialog Usage    QU  Quit
DS  Dialog Summary     IA  Install All
Select Action: Next Screen// Q

```

After completing this dialog install, you will type Q.

```

Component                               Category  Exists
Source:
Date Packed:
Package Version: 2.0P71

Description:
The following Clinical Reminder items were selected for packing:
REMINDER DIALOG
  VA-GP COVID-19 UPDATE JUNE 2022

REMINDER TERM
  VA-REMINDER UPDATE_2_0_296

Keywords:

Components:

+      + Next Screen  - Prev Screen  ?? More Actions  >>
IA  Install all Components      IS  Install Selected Component
Select Action: Next Screen// Q

```

You will then be returned to this screen. At the **Select Action** prompt, type **Q**.

Install complete.

Post Installation

1. Open the COVID-19 Telephone Follow-Up (VA-COVID-19 TELEPHONE FOLLOW-UP) and confirm the version is 9.2
2. Open the COVID-19 Discharge Template (VA-COVID-19 DISCHARGE INSTRUCTIONS) and confirm the version is 6.2

3. (OPTIONAL) Add “Discussed treatment options available” to the plan section of the VA-COVID-19 TELEPHONE FOLLOW UP note if your facility would like these to be discussed and documented when calling the patient for follow up. (optional)

In VistA, using the menu Reminder Dialog Manager, Reminder Dialog, change view to Group view, edit the reminder dialog groups **VAL-GP COVID-19 FOLLOW-UP PLAN EDUCATION** and **VAL-GP COVID-19 FOLLOW-UP PLAN EDUCATION POS**, add SEQUENCE 58, **VAL-GP COVID-19 DISCUSSED TREATMENT OPTIONS**.

Within that group are several treatment options that are disabled, you can enable the options that your site would like to display in the template. If you are not sure what options to add, ask your Infectious disease service.

- VAL-COVID-19 DISCUSSED TREATMENT PAXLOVID
- VAL-COVID-19 DISCUSSED TREATMENT BEBTELOVIMAB
- VAL-COVID-19 DISCUSSED TREATMENT MOLNUPIRAVIR
- VAL-COVID-19 DISCUSSED TREATMENT REMDESIVIR

This is what that section would look like with all options enabled:

Discussed treatment options available

Nirmatrelvir/Ritonavir (Paxlovid) - 5 day oral course (boosted protease inhibitor, contraindicated with salmeterol or rivaroxaban; [Management of Drug Interactions With Nirmatrelvir/Ritonavir \(Paxlovid\)](#))

NURSES: Provider notified of patient's interest in treatment.
Comment:

PROVIDERS: Patient/surrogate gave oral informed consent to the treatment plan.

PROVIDERS: Patient/surrogate did not consent to the treatment plan.

Bebtelovimab - single dose IV (monoclonal antibody)

NURSES: Provider notified of patient's interest in treatment.

PROVIDERS: Patient/surrogate gave oral informed consent to the treatment plan.

PROVIDERS: Patient/surrogate did not consent to the treatment plan.

Molnupiravir - 5 day oral course (polymerase-active agent, contraindicated in pregnancy, requires contraception)

NURSES: Provider notified of patient's interest in treatment.

PROVIDERS: Patient/surrogate gave oral informed consent to the treatment plan.

PROVIDERS: Patient/surrogate did not consent to the treatment plan.
Reason patient declined and expected outcome:
*

Remdesivir - 3 daily IV infusions (polymerase inhibitor)

NURSES: Provider notified of patient's interest in treatment.

PROVIDERS: Patient/surrogate gave oral informed consent to the treatment plan.

PROVIDERS: Patient/surrogate did not consent to the treatment plan.